多能干细胞促进视网膜再生的研究进展
该综述总结了利用多能干细胞来源的视网膜细胞(包括RPE、感光细胞、RGC及视网膜类器官)进行移植治疗视网膜退行性疾病(如AMD、Stargardt病、RP和青光眼)的临床前与临床研究。文章还讨论了间充质干细胞的多功能保护作用,并指出疗效、安全性和免疫排斥是未来需关注的问题。
要点
- 多能干细胞可提供RPE、感光细胞、RGC及视网膜类器官等 unlimited 细胞来源用于移植。
- 细胞替代与神经保护是 rescue 视网膜变性动物模型视觉功能的两种策略。
- 间充质干细胞具有多功能性,可保护退化的视网膜细胞。
核心结论
- 多能干细胞来源的视网膜细胞移植是治疗不可逆视网膜细胞死亡的 promising 方法,但疗效、安全性和免疫排斥仍需进一步研究。
研究设计与样本
- 本文为综述,总结了视网膜退行性疾病细胞死亡机制、视网膜细胞生成方法以及临床前和临床研究的当前发现。
主要发现
- AMD患者中可通过OCT观察到异常的RPE细胞。
- RP患者中RPE和感光细胞层的形态和功能异常由遗传异常引起。
- Stargardt病以黄斑区RPE和感光细胞丢失为特征,导致早期中心视力丧失。
- 青光眼患者中可观察到视网膜神经节细胞(RGC)丢失。
- 多能干细胞可衍生出RPE细胞、感光细胞、RGC及具有层状结构的视网膜类器官。
临床怎么用
- 移植多能干细胞来源的视网膜细胞或使用间充质干细胞进行神经保护,可能成为视网膜退行性疾病的通用治疗策略。
局限性
- 综述指出未来需关注疗效、安全性和免疫排斥问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell replacement therapy is a promising treatment for irreversible retinal cell death in diverse diseases, such as age-related macular degeneration (AMD), Stargardt's disease, retinitis pigmentosa (RP) and glaucoma. These diseases are all characterized by the degeneration of one or two retinal cell types that cannot regenerate spontaneously in humans. Aberrant retinal pigment epithelial (RPE) cells can be observed through optical coherence tomography (OCT) in AMD patients. In RP patients, the morphological and functional abnormalities of RPE and photoreceptor layers are caused by a genetic abnormality. Stargardt's disease or juvenile macular degeneration, which is characterized by the loss of the RPE and photoreceptors in the macular area, causes central vision loss at an early age. Loss of retinal ganglion cells (RGCs) can be observed in patients with glaucoma. Once the retinal cell degeneration is triggered, no treatments can reverse it. Transplantation-based approaches have been proposed as a universal therapy to target patients with various concomitant diseases. Both the replacement of dead cells and neuroprotection are strategies used to rescue visual function in animal models of retinal degeneration. Diverse retinal cell types derived from pluripotent stem cells, including RPE cells, photoreceptors, RGCs and even retinal organoids with a layered structure, provide unlimited cell sources for transplantation. In addition, mesenchymal stem cells (MSCs) are multifunctional and protect degenerating retinal cells. The aim of this review is to summarize current findings from preclinical and clinical studies. We begin with a brief introduction to retinal degenerative diseases and cell death in diverse diseases, followed by methods for retinal cell generation. Preclinical and clinical studies are discussed, and future concerns about efficacy, safety and immunorejection are also addressed.
引用
- Jin ZB, Gao ML, Deng WL, et al. Stemming retinal regeneration with pluripotent stem cells. Prog Retin Eye Res. 2018. PMID: 30419340. doi:10.1016/j.preteyeres.2018.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。